Jose Alexandre Ferreira
Overview
Explore the profile of Jose Alexandre Ferreira including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
45
Citations
1720
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Peixoto A, Ferreira D, Miranda A, Relvas-Santos M, Freitas R, Veth T, et al.
iScience
. 2025 Feb;
28(2):111758.
PMID: 39906564
Bladder tumors with aggressive characteristics often present microenvironmental niches marked by low oxygen levels (hypoxia) and limited glucose supply due to inadequate vascularization. The molecular mechanisms facilitating cellular adaptation to...
2.
Cotton S, Ferreira D, Relvas-Santos M, Brandao A, Afonso L, Miranda A, et al.
Mol Oncol
. 2024 Nov;
19(3):635-658.
PMID: 39508360
Colorectal cancer (CRC) cells express sialylated Lewis antigens (sLe), crucial for metastasis via E-selectin binding. However, these glycoepitopes lack cancer specificity, and E-selectin-targeted glycoproteins remain largely unknown. Here, we established...
3.
Soares J, Eiras M, Ferreira D, Santos D, Relvas-Santos M, Santos B, et al.
Int J Mol Sci
. 2024 Apr;
25(7).
PMID: 38612533
Colorectal cancer (CRC) screening relies primarily on stool analysis to identify occult blood. However, its sensitivity for detecting precancerous lesions is limited, requiring the development of new tools to improve...
4.
Ferreira E, Ferreira D, Relvas-Santos M, Freitas R, Soares J, Azevedo R, et al.
Int J Mol Sci
. 2024 Mar;
25(6).
PMID: 38542435
Muscle-invasive bladder cancer (MIBC) remains a pressing health concern due to conventional treatment failure and significant molecular heterogeneity, hampering the development of novel targeted therapeutics. In our quest for novel...
5.
Pereira F, Domingues M, Vitorino R, Guerra I, Santos L, Ferreira J, et al.
Int J Mol Sci
. 2024 Mar;
25(6).
PMID: 38542319
Bladder cancer (BCa) research relying on Omics approaches has increased over the last few decades, improving the understanding of BCa pathology and contributing to a better molecular classification of BCa...
6.
Freitas R, Ferreira E, Miranda A, Ferreira D, Relvas-Santos M, Castro F, et al.
ACS Nano
. 2024 Mar;
18(14):10088-10103.
PMID: 38535625
Advanced-stage solid primary tumors and metastases often express mucin 16 (MUC16), carrying immature glycans such as the Tn antigen, resulting in specific glycoproteoforms not found in healthy human tissues. This...
7.
Freitas R, Miranda A, Ferreira D, Relvas-Santos M, Castro F, Ferreira E, et al.
J Control Release
. 2024 Feb;
367:540-556.
PMID: 38301927
Cancer presents a high mortality rate due to ineffective treatments and tumour relapse with progression. Cancer vaccines hold tremendous potential due to their capability to eradicate tumour and prevent relapse....
8.
Pocas J, Marques C, Gomes C, Otake A, Pinto F, Ferreira M, et al.
Proc Natl Acad Sci U S A
. 2023 May;
120(20):e2214853120.
PMID: 37155874
Gastric cancer is a dominating cause of cancer-associated mortality with limited therapeutic options. Here, we show that syndecan-4 (SDC4), a transmembrane proteoglycan, is highly expressed in intestinal subtype gastric tumors...
9.
Shi R, Gao Y, Ferreira J, Luo N, Miao H
Front Mol Biosci
. 2023 Apr;
10:1182083.
PMID: 37056724
No abstract available.
10.
Freitas R, Peixoto A, Ferreira E, Miranda A, Santos L, Ferreira J
Biotechnol Adv
. 2023 Apr;
65:108144.
PMID: 37028466
Cancer remains a leading cause of death worldwide due to the lack of safer and more effective therapies. Cancer vaccines developed from neoantigens are an emerging strategy to promote protective...